House Committee Report
El texto subrayado se agregaría a la ley vigente. El texto tachado se eliminaría.
| 89R14527 CJD-F | ||
| By: Harris, Leach, Phelan, Orr, VanDeaver, | H.B. No. 3717 | |
| et al. |
| A BILL TO BE ENTITLED | |
| AN ACT | |
| relating to the establishment of a grant program to fund the United | |
| States Food and Drug Administration's drug development trials with | |
| ibogaine for the purpose of securing the administration's approval | |
| as a medication for treatment of opioid use disorder, co-occurring | |
| substance use disorder, and any other neurological or mental health | |
| conditions for which ibogaine demonstrates efficacy. | |
| BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: | |
| SECTION 1. Subtitle C, Title 6, Health and Safety Code, is | |
| amended by adding Chapter 491 to read as follows: | |
| CHAPTER 491. GRANT PROGRAM FOR DRUG DEVELOPMENT OF IBOGAINE | |
| TREATMENT | |
| Sec. 491.001. DEFINITIONS. In this chapter: | |
| (1) "Commission" means the Health and Human Services | |
| Commission. | |
| (2) "Executive commissioner" means the executive | |
| commissioner of the Health and Human Services Commission. | |
| Sec. 491.002. RULES. The executive commissioner shall | |
| adopt rules necessary to administer this chapter. | |
| Sec. 491.003. ESTABLISHMENT OF GRANT PROGRAM. The | |
| commission shall establish and administer a grant program to fund a | |
| public-private partnership program that will pay for the costs of | |
| the United States Food and Drug Administration's drug development | |
| trials with ibogaine to secure the administration's approval as a | |
| medication for treatment of opioid use disorder, co-occurring | |
| substance use disorder, and any other neurological or mental health | |
| conditions for which ibogaine demonstrates efficacy. | |
| Sec. 491.004. APPLICATION. (a) The commission shall | |
| prepare and issue a notice of funding opportunity to solicit | |
| applications for the grant program established under this chapter. | |
| (b) An applicant may apply to the commission in the form and | |
| manner prescribed by the commission for a grant under this chapter. | |
| To be eligible for a grant, an applicant must: | |
| (1) be a for-profit, nonprofit, or public benefit | |
| corporate entity that has the requisite organizational and | |
| financial capacity to: | |
| (A) conduct the United States Food and Drug | |
| Administration's drug development trials with ibogaine to secure | |
| the administration's approval as a medication for treatment of | |
| opioid use disorder, co-occurring substance use disorder, and any | |
| other neurological or mental health conditions for which ibogaine | |
| demonstrates efficacy; | |
| (B) as a result of the data obtained from the drug | |
| development trial described by Paragraph (A), seek United States | |
| Food and Drug Administration approval of ibogaine; and | |
| (C) conduct future drug development trials of | |
| ibogaine as a medication for treatment of opioid use disorder, | |
| co-occurring substance use disorder, and any other neurological or | |
| mental health conditions for which ibogaine demonstrates efficacy; | |
| and | |
| (2) provide: | |
| (A) a detailed description of the planned | |
| strategy for obtaining approval for the drug development trial from | |
| the United States Food and Drug Administration; | |
| (B) a detailed drug development trial design that | |
| includes: | |
| (i) a description of the composition of the | |
| applicant's drug development trial team and the expertise of the | |
| team members; | |
| (ii) a drug development trial participant | |
| recruitment plan; | |
| (iii) detailed patient screening criteria | |
| and cardiac safety protocols; | |
| (iv) administration protocols; | |
| (v) an aftercare and post-acute treatment | |
| support plan; and | |
| (vi) a data integrity plan; | |
| (C) a proposal to recognize this state's | |
| commercial interest in all patentable intellectual property that | |
| may be generated over the course of the drug development trials, | |
| including: | |
| (i) the treatment that is the subject of the | |
| trials; | |
| (ii) administration protocols; | |
| (iii) treatment models or techniques; and | |
| (iv) technology used in the trials; | |
| (D) a plan to establish a corporate presence in | |
| this state and to promote and maintain ibogaine-related biomedical | |
| research, development, treatment, manufacturing, and distribution | |
| in this state; | |
| (E) a plan to secure third-party payor approval | |
| for ibogaine treatment following approval by the United States Food | |
| and Drug Administration through: | |
| (i) private insurers; | |
| (ii) Medicare; | |
| (iii) Medicaid; and | |
| (iv) the TRICARE program of the United | |
| States Department of Defense; | |
| (F) a plan to ensure ibogaine treatment access to | |
| uninsured individuals following approval by the United States Food | |
| and Drug Administration; | |
| (G) a plan to train and credential medical | |
| providers to administer ibogaine treatment according to developed | |
| clinical standards; and | |
| (H) financial disclosures that verify the | |
| applicant's capacity to fully match state funding. | |
| (c) The commission shall: | |
| (1) make available the application required under this | |
| section; and | |
| (2) announce a period of not less than 90 days during | |
| which applicants may submit an application under this chapter. | |
| Sec. 491.005. SELECTION COMMITTEE. (a) The commission | |
| shall create a selection committee and select the number of | |
| members. The committee must be composed of: | |
| (1) subject matter experts; | |
| (2) philanthropic partners; and | |
| (3) legislative designees. | |
| (b) The selection committee shall review applications, | |
| communicate supplemental inquiries to applicants, and recommend to | |
| the commission the best applicants to conduct the drug development | |
| trials. | |
| (c) The commission shall consider the recommendations of | |
| the selection committee in selecting the applicant to conduct the | |
| ibogaine drug development trial. | |
| Sec. 491.006. INVESTIGATIONAL NEW DRUG APPLICATION. On | |
| notification from the commission that the applicant was selected to | |
| conduct the ibogaine drug development trial, the applicant shall, | |
| as soon as practicable: | |
| (1) submit an investigational new drug (IND) | |
| application with the United States Food and Drug Administration in | |
| accordance with 21 C.F.R. Part 312; and | |
| (2) seek a breakthrough therapy designation for | |
| ibogaine from the United States Food and Drug Administration under | |
| 21 U.S.C. Section 356. | |
| Sec. 491.007. ESTABLISHMENT OF DRUG DEVELOPMENT TRIAL | |
| SITES. On approval of the applicant's investigational new drug | |
| application by the United States Food and Drug Administration, the | |
| commission shall, in consultation with the applicant, establish | |
| drug development trial sites that must be equipped and staffed to | |
| provide cardiac intensive care services to patients. | |
| Sec. 491.008. CONDUCTING DRUG DEVELOPMENT TRIAL. (a) As | |
| soon as practicable after drug development trial sites are | |
| established under Section 491.007, the applicant shall begin a drug | |
| development trial to administer treatment with ibogaine. | |
| (b) The commission, in consultation with the selection | |
| committee under Section 491.005, shall select an institutional | |
| review board with a presence in this state to oversee and verify the | |
| drug development trial research activity for scientific validation | |
| and authentication under the requirements of the United States Food | |
| and Drug Administration. | |
| (c) The applicant shall request the designation under 21 | |
| U.S.C. Section 356 during the drug development trial if the | |
| ibogaine treatment is demonstrating efficacy. | |
| Sec. 491.009. FUNDING. (a) The commission may use money | |
| appropriated to the commission and money received as a gift, grant, | |
| or donation to pay for a grant under this chapter. The commission | |
| may solicit and accept gifts, grants, and donations of any kind and | |
| from any source for purposes of this section. | |
| (b) An applicant selected to perform a drug development | |
| trial under this chapter shall contribute toward the cost of | |
| developing the ibogaine treatment an amount of money that is at | |
| least equal to the amount of money that the applicant received in | |
| the form of a grant from the commission. | |
| SECTION 2. If before implementing any provision of this Act | |
| a state agency determines that a waiver or authorization from a | |
| federal agency is necessary for implementation of that provision, | |
| the agency affected by the provision shall request the waiver or | |
| authorization and may delay implementing that provision until the | |
| waiver or authorization is granted. | |
| SECTION 3. This Act takes effect immediately if it receives | |
| a vote of two-thirds of all the members elected to each house, as | |
| provided by Section 39, Article III, Texas Constitution. If this | |
| Act does not receive the vote necessary for immediate effect, this | |
| Act takes effect September 1, 2025. |
Texto oficial de la Legislatura de Texas. El formato se adaptó para leerlo en Ratifi.